DCM
PEAR

Dupont Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Dupont Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed – – 1838
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1860
2021
Q4 		$0 Sell
2
-49,996
-100% -$446K ﹤0.01% 1918
2021
Q3 		$497K Hold
49,998
– – 0.02% 859
2021
Q2 		$494K Buy
+49,998
New +$490K 0.01% 979

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dupont Capital Management's PEAR Position: Q2 2022 in Review

Dupont Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 2 shares.

Dupont Capital Management first reported a position in PEAR in Q2 2021 and held it in 4 quarters. The position peaked at $497K in Q3 2021. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

  • Dupont Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Dupont Capital Management sold 2 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022.
  • Dupont Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 4 quarters.
  • Dupont Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $497K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.